Repurposing Immunomodulatory Drugs to Combat Tuberculosis [PDF]
Frontiers in Immunology, 2021 Tuberculosis (TB) is an infectious disease caused by an obligate intracellular pathogen, Mycobacterium tuberculosis (M.tb) and is responsible for the maximum number of deaths due to a single infectious agent.
Samreen Fatima +2 more
doaj +5 more sources
Novel immunomodulatory drugs and neo-substrates [PDF]
Biomarker Research, 2020 Thalidomide, lenalidomide and pomalidomide are immunomodulatory drugs (IMiDs) effective in the treatment of multiple myeloma, myelodysplastic syndrome (MDS) with deletion of chromosome 5q and other hematological malignancies.
Shaobing Gao +2 more
doaj +5 more sources
Immunomodulatory drugs have divergent effects on humoral and cellular immune responses to SARS-CoV-2 vaccination in people living with rheumatoid arthritis [PDF]
Scientific Reports, 2023 Understanding the efficacy of SARS-CoV-2 vaccination in people on immunosuppressive drugs, including those with rheumatoid arthritis (RA), is critical for their protection.
Jenna M. Benoit +17 more
doaj +2 more sources
Immunomodulatory and Antioxidant Drugs in Glaucoma Treatment
Pharmaceuticals, 2023 Glaucoma, a group of diseases characterized by progressive retinal ganglion cell loss, cupping of the optic disc, and a typical pattern of visual field defects, is a leading cause of severe visual impairment and blindness worldwide.
Francesco Buonfiglio +2 more
doaj +3 more sources
Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma [PDF]
Frontiers in Oncology, 2023 Multiple Myeloma (MM) is an incurable neoplasm of mature B cells and the second most prevalent hematological malignancy worldwide. While combinations of proteasome inhibitors like bortezomib (Bz) and immunomodulators (IMiDs) like lenalinomide (Len) are ...
Antoine Domenger +6 more
doaj +2 more sources
Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma [PDF]
Frontiers in Oncology, 2022 Resistance to immunomodulatory drugs (IMiDs®) is a major cause of treatment failure, disease relapse and ultimately poorer outcomes in multiple myeloma (MM). In order to optimally deploy IMiDs and their newer derivates CRBN E3 ligase modulators (CELMoDs®)
Lucia Y. Chen +4 more
doaj +2 more sources
Immunomodulatory Drugs in the Management of SARS-CoV-2 [PDF]
Frontiers in Immunology, 2020 With the onset of the global pandemic in 2020 of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), there has been increasing research activity around certain disease-modifying drugs that are used for the management of inflammatory disorders ...
Daniel R. Burrage +4 more
doaj +2 more sources
Influence of immunomodulatory drugs on the gut microbiota. [PDF]
Transl Res, 2021 Immunomodulatory medications are a mainstay of treatment for autoimmune diseases and malignancies. In addition to their direct effects on immune cells, these medications also impact the gut microbiota. Drug-induced shifts in commensal microbes can lead to indirect but important changes in the immune response.
Cohen I, Ruff WE, Longbrake EE.
europepmc +3 more sources
Antibiotics, 2021 Tuberculosis (TB) remains a global health emergency, with an estimated 2 billion people infected across the world, and 1.4 million people dying to this disease every year. Many aspects of the causative agent, Mycobacterium tuberculosis, make this disease
Chiyun Lee, Sanjib Bhakta
doaj +3 more sources
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs [PDF]
Frontiers in Immunology, 2021 Immunomodulatory drugs (IMiDs) are effective treatments for patients with multiple myeloma. IMiDs have pleotropic effects including targeting the myeloma cells directly, and improving the anti-myeloma immune response.
Criselle D'Souza +6 more
doaj +2 more sources